Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

BACKGROUND: Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Alth...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Mengqiu, Song, Chao, Zhang, Yaowen, Xu, Xiaoyu, Wang, Chen, Zhang, Zhanchun, Chen, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606049/
https://www.ncbi.nlm.nih.gov/pubmed/34801029
http://dx.doi.org/10.1186/s12944-021-01596-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606049/
https://www.ncbi.nlm.nih.gov/pubmed/34801029
http://dx.doi.org/10.1186/s12944-021-01596-5

Ejemplares similares